Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NWU2016-08-02||CLO-Northwestern University||A Phase I Single-Arm, Multicenter Pilot Study Aimed at Validating Gamma-OHPdG as a Biomarker and Testing the Effects of Polyphenon E® on its Levels in Patients with Cirrhosis||Cancer Prevention and Control CIRB||Available to Open|
|9846||ETCTN||Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10183||ETCTN||A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10346||ETCTN||Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|RTOG-0232||RTOG||A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-10603||CALGB||A Phase III Randomized; Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1607||SWOG||A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|EAE161||ECOG-ACRIN||Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|AREN0532||COG||Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|ADVL1515||COG||A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors||Pediatric CIRB||Available to Open|